XRCC1 rs25487基因多态性对于ⅢB~Ⅳ期非小细胞肺癌患者使用铂类联合方案无进展生存期的影响  

Influence of XRCC1 rs25487 gene polymorphism on progression-free survival of stageⅢB-ⅣNSCLC patients with platinum-based chemotherapy

作　　者：陈泳伍 王崇薇 尤铖瑛 张欣格 沈爱宗 张蕾[1,3] CHEN Yongwu;WANG Chongwei;YOU Chengying;ZHANG Xinge;SHEN Aizong;ZHANG Lei(Department of Pharmacy,The First Affiliated Hospital of USTC,Division of Life Sciences and Medicine,University of Science and Technology of China,Anhui Hefei 230001,China;Drug Clinical Trail Institution,The First Affiliated Hospital of USTC,Division of Life Sciences and Medicine,University of Science and Technology of China,Anhui Hefei 230001,China;Institute of Clinical Pharmacology,Anhui Medical University,Key Laboratory for Anti-inflammatory and Immune Medicine,Ministry of Education,Anhui Hefei 230032,China)

机构地区：[1]中国科学技术大学附属第一医院(安徽省立医院)药学部,安徽合肥230001 [2]中国科学技术大学附属第一医院(安徽省立医院)药物临床试验机构,安徽合肥230001 [3]安徽医科大学临床药理研究所/抗炎免疫药物教育部重点实验室,安徽合肥230032

出　　处：《中国医院药学杂志》2023年第19期2198-2201,共4页Chinese Journal of Hospital Pharmacy

基　　金：安徽省重点研究与开发计划项目(编号:201904a07020092);安徽省自然科学基金项目(编号:2108085MH311);安徽省教育厅高等学校省级质量工程项目(重大)(编号:2020jyxm2327);安徽省高等学校省级质量工程教学研究项目(编号:2019jyxm0972)。

摘　　要：目的:探讨X线修复交错互补基因1(XRCC1)rs25487基因多态性对于晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者使用铂类联合方案无进展生存期的影响。方法:收集中国科学技术大学附属第一医院(安徽省立医院)2020年8月—2022年4月期间收治的ⅢB~Ⅳ期NSCLC患者血液标本并行XRCC1 rs25487基因型鉴定,随访其铂类联合方案治疗无进展生存期并记录性别、年龄、病理类型、肿瘤转移部位等临床特征,分析患者基因表型对于预后的影响。结果:该研究共纳入93例患者,Log-rank检验结果显示,XRCC1 rs25487 GG型患者中位PFS显著优于AG/AA型患者(100.0 d vs.79.0 d,P=0.0445)。COX多因素回归结果显示XRCC1 rs25487基因型为患者使用铂类联合方案治疗PFS的独立影响因素(P=0.0285)。结论:晚期NSCLC患者可通过检测XRCC1 rs25487表型预测其铂类治疗的敏感性,为临床治疗决策提供有效参考。OBJECTIVE To investigate the influence of X-ray repair cross complementing gene 1 XRCC1 rs25487 polymorphism on progression-free survival of patients with stageⅢB-Ⅳnon-small cell lung cancer with platinum-based chemotherapy.METHODS Blood samples were collected from patients with stageⅢB-ⅣNSCLC who were admitted to The First Affiliated Hospital of USTC from August 2020 to April 2022,and their XRCC1 rs25487 genotype was identified.The progression-free survival time of the patients with platinum-based chemotherapy was followed up,and clinical characteristics such as gender,age,pathological type,and tumor metastasis site were recorded.The impact of XRCC1 rs25487 genotype on the prognosis of patients was analyzed.RESULTS A total of 93 patients were included in this study.Log-rank test results showed that the median PFS of XRCC1 rs25487 GG patients was significantly better than that of AG/AA patients(100.0 d vs.79.0 d,P=0.0445).The results of COX multivariate regression showed that XRCC1 rs25487 genotype was an independent factor for PFS of patients with platinum-based combination therapy(P=0.0285).CONCLUSION Advanced NSCLC patients should detect XRCC1 rs25487 phenotype in order to predict their sensitivity of platinum,which can provide effective reference for clinical treatment decisions.

关 键 词：XRCC1 rs25487 非小细胞肺癌 铂类药物 

分 类 号：R979.11[医药卫生—药品]